Glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide had been proved to sustain weight loss in obese patients and were associated with the reversal of prediabetes to normoglycemia during 1–2 years of follow-up (1) and another study showed that 3.0 mg of liraglutide was an adjunct to diet and exercise, associated with reduced body weight and improved metabolic control (27). Here, GCG is linked to prediabetes syndrome.